WO2017040993A1 - Small molecule inhibitors of dyrk1a and uses thereof - Google Patents
Small molecule inhibitors of dyrk1a and uses thereof Download PDFInfo
- Publication number
- WO2017040993A1 WO2017040993A1 PCT/US2016/050198 US2016050198W WO2017040993A1 WO 2017040993 A1 WO2017040993 A1 WO 2017040993A1 US 2016050198 W US2016050198 W US 2016050198W WO 2017040993 A1 WO2017040993 A1 WO 2017040993A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- disease
- dyrk1a
- nmr
- mhz
- compound
- Prior art date
Links
- DCDACYMXQMMGCQ-UHFFFAOYSA-N C[n]1ncc(-c(cc2)cc3c2nc[n]3-c(cc2)ccc2C#N)c1 Chemical compound C[n]1ncc(-c(cc2)cc3c2nc[n]3-c(cc2)ccc2C#N)c1 DCDACYMXQMMGCQ-UHFFFAOYSA-N 0.000 description 2
- CDRWFGZAMCVDOU-UHFFFAOYSA-N C[n]1ncc(-c(cc2)cc3c2nc[n]3-c(cc2)ccc2C(O)=O)c1 Chemical compound C[n]1ncc(-c(cc2)cc3c2nc[n]3-c(cc2)ccc2C(O)=O)c1 CDRWFGZAMCVDOU-UHFFFAOYSA-N 0.000 description 2
- MXXCMEPUMPPYJB-UHFFFAOYSA-N N#Cc(cc1)ccc1-[n]1c(cc(cc2)Br)c2nc1 Chemical compound N#Cc(cc1)ccc1-[n]1c(cc(cc2)Br)c2nc1 MXXCMEPUMPPYJB-UHFFFAOYSA-N 0.000 description 2
- GQIAXTYZOCBTQL-UHFFFAOYSA-N C1c(cc(cc2)-[n]3c(cc(cc4)-c5ccncc5)c4nc3)c2OC1 Chemical compound C1c(cc(cc2)-[n]3c(cc(cc4)-c5ccncc5)c4nc3)c2OC1 GQIAXTYZOCBTQL-UHFFFAOYSA-N 0.000 description 1
- PYQNJRSZWLZPTI-UHFFFAOYSA-N C=CN/N=C\N=C/Nc(cc1)ccc1C#N Chemical compound C=CN/N=C\N=C/Nc(cc1)ccc1C#N PYQNJRSZWLZPTI-UHFFFAOYSA-N 0.000 description 1
- KOLZBASUCTVYJF-UHFFFAOYSA-N CC(N(CC1)CCC1C(Nc1nc(ccc(-c2ccncc2)c2)c2[n]1-c(cc1)ccc1OC)=O)=O Chemical compound CC(N(CC1)CCC1C(Nc1nc(ccc(-c2ccncc2)c2)c2[n]1-c(cc1)ccc1OC)=O)=O KOLZBASUCTVYJF-UHFFFAOYSA-N 0.000 description 1
- JZKBWSBNYOILOT-RWGGQARRSA-N CC/C=C/N(/C=N\[C@@H](C)/C=N\N(C)C=C)c(cc1)ccc1C#N Chemical compound CC/C=C/N(/C=N\[C@@H](C)/C=N\N(C)C=C)c(cc1)ccc1C#N JZKBWSBNYOILOT-RWGGQARRSA-N 0.000 description 1
- UYUYPUAVTGHWFX-UHFFFAOYSA-N CCN(C)/N=C\N=C/Nc(cc1)ccc1C(N)=O Chemical compound CCN(C)/N=C\N=C/Nc(cc1)ccc1C(N)=O UYUYPUAVTGHWFX-UHFFFAOYSA-N 0.000 description 1
- MWWMNIYVWVMTGO-UHFFFAOYSA-N CCN/N=C\N=C/Nc(cc1)ccc1C(N)=O Chemical compound CCN/N=C\N=C/Nc(cc1)ccc1C(N)=O MWWMNIYVWVMTGO-UHFFFAOYSA-N 0.000 description 1
- PLMRVOAZLQZMLA-UHFFFAOYSA-N CS(c(cc1)ccc1-[n]1c(cc(cc2)-c(cc3)ccc3OC(F)(F)F)c2nc1)(=O)=O Chemical compound CS(c(cc1)ccc1-[n]1c(cc(cc2)-c(cc3)ccc3OC(F)(F)F)c2nc1)(=O)=O PLMRVOAZLQZMLA-UHFFFAOYSA-N 0.000 description 1
- NMJOPIRKNGLUFZ-UHFFFAOYSA-N CS(c(cc1)ccc1-c1cnc(cc2)[n]1cc2-c1ccncc1)(=O)=O Chemical compound CS(c(cc1)ccc1-c1cnc(cc2)[n]1cc2-c1ccncc1)(=O)=O NMJOPIRKNGLUFZ-UHFFFAOYSA-N 0.000 description 1
- JWMSJUISXGZDDR-UHFFFAOYSA-N C[n]1ncc(-c(cc2)cc3c2nc[n]3-c(cc2)ccc2C(N)=O)c1 Chemical compound C[n]1ncc(-c(cc2)cc3c2nc[n]3-c(cc2)ccc2C(N)=O)c1 JWMSJUISXGZDDR-UHFFFAOYSA-N 0.000 description 1
- FVOJNNOEIDQDRS-UHFFFAOYSA-N c1cnc(cc2)[n]1cc2-c1c[nH]nc1 Chemical compound c1cnc(cc2)[n]1cc2-c1c[nH]nc1 FVOJNNOEIDQDRS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- This invention is in the field of medicinal chemistry.
- the invention relates to a new class of small-molecules having a benzimidazole or imidazopyridine structure which function as inhibitors of DYRK1A protein, and their use as therapeutics for the treatment of Alzheimer's disease, Down syndrome, glioblastoma, autoimmune diseases, inflammatory disorders (e.g., airway inflammation), and other diseases.
- AD Alzheimer's disease
- the underlying treatment of learning and/or memory disorders is a huge and significantly unmet medical need and also included learning and memory repair after, for example, incidents of stroke or significant brain damage. As such, an improved understanding of the dementia (and other neuropathology) and related improved treatment methods are needed.
- NFTs neuroofibrillary tangles
- DYRKIA phosphorylation regulated kinase-1 A
- AD Alzheimer's disease
- DS Down syndrome critical region
- DYRKIA decreased expression of the DYRKIA gene has been implicated in both the cognitive deficits of Down syndrome (DS) and the early onset of tau and amyloid neuropathologies that are associated with this genetic disorder.
- DYRKIA levels are increased in transgenic mouse models of DS and develop DS-like phenotypes including hippocampal-dependent spatial learning and memory deficits and developmental delays. Together these data strongly support a central function for DYRKIA in cognitive deficits associated with DS.
- inhibition of excess DYRKIA activity has been shown to improve these DYRKlA-mediated cognitive deficits after administration of the natural products epigallocatechin-3-gallate (EGCg) and harmine, the standards for DYRKIA inhibition at the on-set of this translational campaign.
- ECCg epigallocatechin-3-gallate
- DYRKIA inhibitors described herein can also be considered as potential
- DYRKIA inhibitors of the present invention have been also implicated as potential therapeutics for the treatment of glioblastomas and further potential utility is highlighted in the oncology arena (see, e.g., Ionescu et al, Mini-reviews in Medicinal Chemistry, 2012, 12, 1315-1329).
- DYRKIA inhibitors may also have utility as general cognitive enhancers, given the published findings that DYRKIA can phosphorylate sirtuin 1 , a key regulator of learning and memory (see, e.g., Michan et al, J. Neurosci. 2010, 30(29), 9695-9707; Guo et al, J Biol. Chem. 2010, 285 (17), 13223-13232).
- the potential utility of these DYRKIA compound series is further reinforced by findings that harmine, a potent, but relatively less selective DYRKIA inhibitor, enhances memory performance in wild-type rodents (Mennenga et al, Physiol. Behav. 2015, 138, 260-265).
- DYRKIA as a physiologically relevant regulator of T reg cell differentiation and suggest a broader role for other DYRK family members in immune homeostasis. As such, new roles may be found in autoimmune diseases such as inflammatory bowel disease and type 1 diabetes (see, e.g., Khor B, et al, eLife 2015;4: e05920).
- this invention relates to a new class of small-molecules having a benzimidazole or imidazopyridine structure which function as inhibitors of DYRKIA protein, and their use as therapeutics for the treatment of disorders related to DYRKIA activity (e.g., AD, DS, neuropathology, glioblastoma, autoimmune diseases, inflammatory disorders (e.g., airway inflammation)).
- disorders related to DYRKIA activity e.g., AD, DS, neuropathology, glioblastoma, autoimmune diseases, inflammatory disorders (e.g., airway inflammation)
- benzimidazole and imidazo ridine compounds e.g., benzimidazole and imidazo ridine compounds
- Formula I is not limited to a particular chemical moiety for Rl, R2, R3, R4, X, Y and Z.
- the particular chemical moiety for Rl, R2, R3, R4, X, Y and Z independently include any chemical moiety that permits the resulting compound to inhibit DYRKIA activity.
- the particular chemical moiety for Rl, R2, R3, R4, X, Y and Z independently include any chemical moiety that permits the resulting compound to inhibit one or more of: DYRKIA related PI3K/Akt signaling; DYRKIA related tau
- X-Y-Z is , thereby rendering the resulting compound a benzimidazole compound having the following formula:
- X-Y-Z is , thereb rendering the compound
- Rl is selected from hydrogen, aryl and substituted aryl
- R5 is selected from hydrogen, alkoxy, alkylsulfonyl, cyano, carboxy, ester, amido, substituted amido, sulfonamide, substituted sulfonamide, methylenedioxy, heterocyclyl alkyl, heterocyclyl, and heterocyclyl alkyl amido, a lipophilic moiety comprising
- R6 is selected from hydrogen, C1 -C4 alkyl, heterocyclyl alkyl, heteroaryl alkyl, aryl alkyl, aryl, heterocyclyl, and heteroaryl.
- R7 is selected from hydrogen, alkoxy, alkylsulfonyl, cyano, carboxy, ester, amido, substituted amido, sulfonamide, substituted sulfonamide, methylenedioxy, heterocyclyl alkyl, heterocyclyl, and heterocyclyl alkyl amido, a lipophilic moiety comprising
- each of R2 and R3 is independently selected from hydrogen, aryl,
- the compound is one or more of the compounds shown in Examples II and/or III.
- the invention further provides processes for preparing any of the compounds of the present invention.
- the invention also provides the use of compounds to not only inhibit DYRKIA activity but also signaling pathways dependent upon DYRKIA phosphorylation (e.g., Tau, POK/AKt, APP, PSI, ASF, RCAN-1 , NFAT, p53, ASK1/JNK1, SIRT1 , GluN2A and other NMD A receptors).
- the invention also relates to the use of compounds for sensitizing cells to additional agent(s), such as agents known to be effective in the treatment of neurodegenerative disorders.
- the compounds of the invention are useful for the treatment, amelioration, or prevention of disorders associated with DYRKIA activity (e.g., AD, DS, Parkinson's disease, Huntington's disease, glioblastoma), such as those responsive to DYRKIA activity inhibition.
- the compounds can be used to treat, ameliorate, or prevent cancer that is associated with DYRKIA activity (e.g., glioblastoma).
- the compounds can be used to treat, ameliorate, or prevent autoimmune diseases.
- the compounds can be used to treat, ameliorate, or prevent inflammatory disorders (e.g., airway inflammation).
- the invention also provides pharmaceutical compositions comprising the compounds of the invention in a pharmaceutically acceptable carrier.
- kits comprising a compound of the invention and instructions for administering the compound to an animal.
- the kits may optionally contain other therapeutic agents, e.g., agents useful in treating neurodegenerative disorders and/or anticancer agents.
- each of the "*" substituents is independently Carbon or Nitrogen, and X, Y, Z, Rl, R2, R3, and R4 are as described above.
- FIG. 1 presents a flow chart describing a screening paradigm for DYRKIA inhibitor progression.
- DYRKIA is a member of the DYRK family containing 5 kinases (DYRKIA, DYRK1B, DYRK2, DYRK3 and DYRK4).
- DYRKs belong to the CMGC group of proline-directed kinases, which also includes cyclin-dependent kinases (CDKs), mitogen-activated protein kinases (MAPKs), glycogen synthase kinases (GSKs) and CDC2-like kinases (CLKs). While the signaling pathways of CDK and MAPK families have been extensively studied, much less is known on how DYRKs and CLKs are linked to other proteins and various physiological or pathological processes.
- CDKs cyclin-dependent kinases
- MAPKs mitogen-activated protein kinases
- GSKs glycogen synthase kinases
- CLKs CDC2-like kinases
- the DYRKIA gene is located on chromosome 21 (21q22.2), a region known as the Down-Syndrome Critical Region (DSCR) (see, e.g., Hammerle et al., 2011 Development 138, 2543-2554).
- DSCR Down-Syndrome Critical Region
- the under- or over-expression of the Dyrkla gene in mammals or of its orthologous gene minibrain (mnb) in Drosophila causes severe retardation of central nervous system development and maturation.
- DYRKIA phosphorylates the nuclear factor of activated T cells (NFAT), counteracting the effect of calcium signaling and maintaining inactive NFAT (see, e.g., Arron et al, 2006 Nature 411, 595-600).
- DYRKIA has been identified as a negative regulator of the cell cycle that promotes the switch to a quiescent state or differentiation (see, e.g., Chen et al., 2013 Mol. Cell 52, 87-100). In malignant cells, DYRKIA promotes survival via inhibition of pro-apoptotic proteins (see, e.g., Guo et al., 2010 J. Bio. Chem. 285, 13223-13232; Seifert et al, 2008 FEBS J. 275, 6268-6280).
- the DYRKIA inhibitors of the present invention provide a new avenue for pharmaceutical intervention of mental impairment associated with AD and other neurodegenerative diseases, and address a critical unmet medical need and significantly changing treatment paradigm for AD.
- Benzimidazole and imidazopyridine compounds as inhibitors of the dual specificity tyrosine phosphorylation regulated kinase- 1 A (DYRKIA) and their potential for use as therapeutics against AD and other disorders related to DYRK-1A activity (e.g., DS, other neuropathology, cancer (e.g., glioblastoma)).
- DYRKIA dual specificity tyrosine phosphorylation regulated kinase- 1 A
- Many benzimidazole and imidazopyridine compounds were also shown to exhibit activity against DYRK1B and exhibit some degree of activity against other kinases implicated in a variety of disease states.
- the DYRKIA inhibitors of the present invention can be used for treating other cellular pathways involved in mental impairment and neurodegenerative dementia.
- the DYRKIA inhibitors of the present invention can be used for inhibiting DYRKIA activated PI3K/Akt signaling, a pathway largely involved in neuronal development, growth, and survival.
- the DYRKIA inhibitors of the present invention DYRKIA can be used for inhibiting DYRKIA stimulated ASK1/JNK1 activity, thereby inducing neuronal death and apoptosis.
- the DYRKIA inhibitors of the present invention DYRKIA can be used to inhibit DYRKIA phosphorylation of p53 during embryonic brain development, thereby preventing neuronal proliferation alteration.
- the DYRKIA inhibitors of the present invention can be used to inhibit DYRKIA phosphorylation of synaptic proteins Amph 1, Dynamin 1, and Synaptojanin, involved in the regulation of endocytosis, thereby retaining synaptic plasticity through preventing alteration of the number, size, and morphology of dendritic spines.
- the DYRKIA inhibitors of the present invention can be used to inhibit presenilin 1 (the catalytic sub-unit of ⁇ -secretase).
- the present invention addresses the need for effective therapies for AD and DS by providing potent and selective DYRKIA inhibitors able to permeate the blood-brain barrier (BBB) and elicit on-mechanism therapeutic responses in AD animal models.
- BBB blood-brain barrier
- this invention relates to a new class of small-molecules having a benzimidazole or imidazopyridine structure which function as inhibitors of DYRKIA protein, and their use as therapeutics for the treatment of Alzheimer's disease, Down syndrome, glioblastoma, autoimmune diseases, inflammatory disorders (e.g., airway inflammation), and other diseases.
- Formula I is not limited to a particular chemical moiety for Rl , R2, R3, R4, X, Y and Z.
- the particular chemical moiety for Rl, R2, R3, R4, X, Y and Z independently include any chemical moiety that permits the resulting compound to inhibit DYRKIA activity.
- the particular chemical moiety for Rl, R2, R3, R4, X, Y and Z independently include any chemical moiety that permits the resulting compound to inhibit one or more of: DYRKIA related PI3K/Akt signaling; DYRKIA related tau
- X-Y-Z is , thereby rendering the resulting
- X-Y-Z is , hereby rendering the compound an
- imidazopyridine compound having the following formula:
- Rl is selected from hydrogen, aryl and substituted aryl
- R5 is selected from hydrogen, alkoxy, alkylsulfonyl, cyano, carboxy, ester, amido, substituted amido, sulfonamide, substituted sulfonamide, methylenedioxy, heterocyclyl alkyl, heterocyclyl, and heterocyclyl alkyl amido, a lipophilic moiety comprising
- R6 is selected from hydrogen, C1-C4 alkyl, heterocyclyl alkyl, heteroaryl alkyl, aryl alkyl, aryl, heterocyclyl, and heteroaryl.
- R7 is selected from hydrogen, alkoxy, alkylsulfonyl, cyano, carboxy, ester, amido, substituted amido, sulfonamide, substituted sulfonamide, methylenedioxy, heterocyclyl alkyl, heterocyclyl, and heterocyclyl alkyl amido, a lipophilic moiety comprising
- each of R2 and R3 is independentl from hydrogen, aryl,
- R4 is selected from hydrogen, NH 2 ,
- the compound is one or more of the compounds shown in
- the invention further provides processes for preparing any of the compounds of the present invention.
- compositions and methods of the present invention are used to treat diseased cells, tissues, organs, or pathological conditions and/or disease states in an animal (e.g. , a mammalian patient including, but not limited to, humans and veterinary animals).
- an animal e.g. , a mammalian patient including, but not limited to, humans and veterinary animals.
- various diseases and pathologies are amenable to treatment or prophylaxis using the present methods and compositions.
- a non-limiting exemplary list of these diseases and conditions includes, but is not limited to, Alzheimer's disease, Down syndrome, Huntington's disease, Parkinson's disease, autoimmune diseases, inflammatory disorders (e.g., airway inflammation), any neurodegenerative disorder related to DYRK1 A activity, and any type of cancer related to DYRK1A activity.
- Some embodiments of the present invention provide methods for administering an effective amount of a compound of the invention and at least one additional therapeutic agent (including, but not limited to, any agent useful in treating Alzheimer's disease, Down syndrome, Huntington's disease, Parkinson's disease, autoimmune diseases, inflammatory disorders (e.g., airway inflammation), any neurodegenerative disorder related to DYRKl A activity, and any type of cancer characterized related to DYRKl A activity).
- additional therapeutic agent including, but not limited to, any agent useful in treating Alzheimer's disease, Down syndrome, Huntington's disease, Parkinson's disease, autoimmune diseases, inflammatory disorders (e.g., airway inflammation), any neurodegenerative disorder related to DYRKl A activity, and any type of cancer characterized related to DYRKl A activity).
- compositions within the scope of this invention include all compositions wherein the compounds of the present invention are contained in an amount which is effective to achieve its intended purpose. While individual needs vary, determination of optimal ranges of effective amounts of each component is within the skill of the art.
- the compounds may be administered to mammals, e.g. humans, orally at a dose of 0.0025 to 50 mg/kg, or an equivalent amount of the pharmaceutically acceptable salt thereof, per day of the body weight of the mammal being treated for disorders responsive to induction of apoptosis. In one embodiment, about 0.01 to about 25 mg/kg is orally administered to treat, ameliorate, or prevent such disorders.
- the dose is generally about one-half of the oral dose.
- a suitable intramuscular dose would be about 0.0025 to about 25 mg/kg, or from about
- the unit oral dose may comprise from about 0.01 to about 1000 mg, for example, about 0.1 to about 100 mg of the compound.
- the unit dose may be administered one or more times daily as one or more tablets or capsules each containing from about 0.1 to about 10 mg, conveniently about 0.25 to 50 mg of the compound or its solvates.
- the compound may be present at a concentration of about 0.01 to
- the compound is present at a concentration of about 0.07-1.0 mg/ml, for example, about 0.1-0.5 mg/ml, and in one embodiment, about 0.4 mg/ml.
- the compounds of the invention may be administered as part of a pharmaceutical preparation containing suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the compounds into preparations which can be used pharmaceutically.
- suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the compounds into preparations which can be used pharmaceutically.
- the preparations particularly those preparations which can be administered orally or topically and which can be used for one type of administration, such as tablets, dragees, slow release lozenges and capsules, mouth rinses and mouth washes, gels, liquid suspensions, hair rinses, hair gels, shampoos and also preparations which can be administered rectally, such as suppositories, as well as suitable solutions for administration by intravenous infusion, injection, topically or orally, contain from about 0.01 to 99 percent, in one embodiment from about 0.25 to 75 percent of active compound(s), together with the excipient.
- compositions of the invention may be administered to any patient which may experience the beneficial effects of the compounds of the invention.
- mammals e.g., humans, although the invention is not intended to be so limited.
- Other patients include veterinary animals (cows, sheep, pigs, horses, dogs, cats and the like).
- the compounds and pharmaceutical compositions thereof may be administered by any means that achieve their intended purpose.
- administration may be by parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, buccal, intrathecal, intracranial, intranasal or topical routes.
- administration may be by the oral route.
- the dosage administered will be dependent upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.
- compositions of the present invention are manufactured in a manner which is itself known, for example, by means of conventional mixing, granulating, dragee- making, dissolving, or lyophilizing processes.
- pharmaceutical preparations for oral use can be obtained by combining the active compounds with solid excipients, optionally grinding the resulting mixture and processing the mixture of granules, after adding suitable auxiliaries, if desired or necessary, to obtain tablets or dragee cores.
- Suitable excipients are, in particular, fillers such as saccharides, for example lactose or sucrose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, as well as binders such as starch paste, using, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone.
- fillers such as saccharides, for example lactose or sucrose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, as well as binders such as starch paste, using, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methyl cellulose,
- disintegrating agents may be added such as the above- mentioned starches and also carboxymethyl-starch, cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate.
- Auxiliaries are, above all, flow-regulating agents and lubricants, for example, silica, talc, stearic acid or salts thereof, such as magnesium stearate or calcium stearate, and/or polyethylene glycol.
- Dragee cores are provided with suitable coatings which, if desired, are resistant to gastric juices.
- concentrated saccharide solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, polyethylene glycol and/or titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures.
- suitable cellulose preparations such as acetylcellulose phthalate or hydroxypropylmethylcellulose phthalate, are used.
- Dye stuffs or pigments may be added to the tablets or dragee coatings, for example, for identification or in order to characterize combinations of active compound doses.
- Other pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol.
- the push-fit capsules can contain the active compounds in the form of granules which may be mixed with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
- the active compounds are in one embodiment dissolved or suspended in suitable liquids, such as fatty oils, or liquid paraffin.
- stabilizers may be added.
- Possible pharmaceutical preparations which can be used rectally include, for example, suppositories, which consist of a combination of one or more of the active compounds with a suppository base.
- Suitable suppository bases are, for example, natural or synthetic triglycerides, or paraffin hydrocarbons.
- gelatin rectal capsules which consist of a combination of the active compounds with a base.
- Possible base materials include, for example, liquid triglycerides, polyethylene glycols, or paraffin hydrocarbons.
- Suitable formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form, for example, water-soluble salts and alkaline solutions.
- suspensions of the active compounds as appropriate oily injection suspensions may be administered.
- Suitable lipophilic solvents or vehicles include fatty oils, for example, sesame oil, or synthetic fatty acid esters, for example, ethyl oleate or triglycerides or polyethylene glycol-400.
- Aqueous injection suspensions may contain substances which increase the viscosity of the suspension include, for example, sodium carboxy methyl cellulose, sorbitol, and/or dextran.
- the suspension may also contain stabilizers.
- the topical compositions of this invention are formulated in one embodiment as oils, creams, lotions, ointments and the like by choice of appropriate carriers.
- Suitable carriers include vegetable or mineral oils, white petrolatum (white soft paraffin), branched chain fats or oils, animal fats and high molecular weight alcohol (greater than C 12 ).
- the carriers may be those in which the active ingredient is soluble.
- Emulsifiers, stabilizers, humectants and antioxidants may also be included as well as agents imparting color or fragrance, if desired.
- transdermal penetration enhancers can be employed in these topical formulations. Examples of such enhancers can be found in U.S. Pat. Nos. 3,989,816 and 4,444,762; each herein
- Ointments may be formulated by mixing a solution of the active ingredient in a vegetable oil such as almond oil with warm soft paraffin and allowing the mixture to cool.
- a vegetable oil such as almond oil
- a typical example of such an ointment is one which includes about 30% almond oil and about 70% white soft paraffin by weight.
- Lotions may be conveniently prepared by dissolving the active ingredient, in a suitable high molecular weight alcohol such as propylene glycol or polyethylene glycol.
- compositions, and methods of the present invention are compositions, and methods of the present invention.
- Other suitable modifications and adaptations of the variety of conditions and parameters normally encountered in clinical therapy and which are obvious to those skilled in the art are within the spirit and scope of the invention.
- HSA21 Human chromosome 21 trisomy results in Down syndrome (DS) (OMIM 190685) and is one of the most common human chromosomal disorders, occurring in ⁇ 1 in 700 live births. While the trisomy usually affects every tissue, reduced cognitive ability is among the most limiting features (see, Lott IT, et al., Lancet neurology 2010;9:623-633; Megarbane A, et al., Genet Med 2009; 1 1 :61 1 -616). Therapies that address cognitive restrictions of DS could have a significant impact for individuals living with this disorder. To this end, normalizing expression levels or the function of critical genes on chromosome 21 could prevent or reverse the deleterious effects of gene overdose.
- Ts65Dn Three main murine models for DS have been developed (Ts65Dn (see, Reeves RH, et al, Nat Genet 1995;11 : 177-184), TslCje (see, Sago H, et al, PNAS 1998;95:6256-6261), and TslRhr (see, Belichenko NP, et al, J Neurosci 2009;29:5938-5948)) that exhibit partial trisomy of chromosome 16, the murine ortholog to human chromosome 21.
- the trisomic region of MMU16 contains the gene for dual-specificity tyrosine-(Y)- phosphorylation regulated kinase 1A (DYRK1A), a member of the CMGC family of kinases.
- DRRK1A dual-specificity tyrosine-(Y)- phosphorylation regulated kinase 1A
- mice show characteristic symptoms of DS including learning and behavioral deficits (see, Reeves RH, et al, Nat Genet 1995;11 : 177-184; Sago H, et al, PNAS 1998;95:6256-6261 ; Belichenko NP, et al, J Neurosci 2009;29:5938-5948) and alterations in their dendritic spines within the hippocampus and cortical regions of the brain (see, Belichenko NP, et al, J Neurosci 2009;29:5938-5948; Belichenko PV, et al, J Comp Neurol 2004;480:281-298;
- mice have also been prepared using a yeast artificial chromosome YAC 152F7 bearing extra copies of five different genes found in the DS critical region (DSCR) of human chromosome 21 including DYRKIA, PIGP, TTC3, DSCR9, and DSCR3. These mice demonstrate that
- mice transgenic for the yeast artificial chromosome YAC 141G6 which contains all genes encompassed in YAC 152F7 except DYRKIA do not exhibit noticeable cognitive impairment.
- mouse models that are transgenic for the human B AC gene (DYRKIA BAC Tg) or a murine BAC clone (TgDYRKlA) have been generated that specifically overexpress either human or murine DYRKIA, respectively.
- mice similarly exhibit DS phenotypes including hippocampal-dependent spatial learning and motor deficits and developmental delays, which is highly suggestive of a central function for DYRKIA in mental deficits associated with DS (see, Smith DJ, et al., Nat Genet 1997;16:28-36; Ahn KJ, et al.,Neurobiol Dis 2006;22:463-472; Altafaj X, et al, Hum Mol Genet 2001 ;10: 1915-1923).
- Harmine 3 is a ⁇ -carboline alkaloid with a reported IC50 of 80 nM against DYRKIA (see, Bain J, et al, Biochem J 2003;371 : 199-204; Bain J, et al, Biochem J 2007;408:297-315).
- DYRKIA ⁇ -carboline analogues, including harmine, have significant drawbacks to consider when exploring their potential therapeutic applications.
- MPTP is converted to MPP+ in the brain, affecting the extrapyramidal dopaminergic system leading to permanent Parkinson' s-like symptoms (see, Albores R, et al, PNAS 1990;87:9368-9372). Due to their convulsive properties observed in vivo, it has been suggested that harmine and its analogues are likely susceptible to similar metabolic pathways. Harmine 3 also exhibits potent inhibition of monoamine oxidase-A (MAO-A) reuptake, leading to behavioral side effects (Ki 5 nM, IC50 2 nM) (see, Reeves RH, et al, Nat Genet 1995;11 : 177-184).
- MAO-A monoamine oxidase-A
- H-bond donor count (CSF2, Box 2, Figure 1) (see, Hitchcock SA, J. Med. Chem, 2006, 49(26), 7559- 83).
- DYRK1B is over-expressed in certain cancer cells including colon, ovarian and pancreatic and could be an attractive target for cancer therapy (see, Deng X, et al., Genes & Cancer (2014), 5(9-10), 337-347; Berger F, et al, Ger. Offen. (2014), DE 102014009011 Al 20141218; Anderson K, et al, Bioorg. Med. Chem. Lett., 2013, 23(24), 6610-6615).
- DYRKIA kinase assay utilizes an EZ Reader Electrophoresis Mobility Chip Instrument (Caliper Life Science).
- 8.7 nM recombinant DYRKIA enzyme is pre-incubated with the small molecule inhibitor, or control buffer, for 5-10 min. To date, these classes of inhibitors are directly competitive with ATP.
- a substrate mix containing 100 ⁇ ATP, 20 mM MgCl2, and 3 ⁇ fluorescently labeled substrate peptide (Caliper LS, FL-peptide 24, KKISGRLSPIM) is added to give a final concentration of 0.8 nM enzyme, 45 ⁇ ATP, 9.1 mM MgCl2, and 1.4 ⁇ substrate peptide within each reaction well.
- the phosphorylation level of the substrate peptide may then be determined.
- the assay is performed in a 384-well-plate format in which 112 compounds can be evaluated at a single concentration in triplicate, or 14 compounds can be evaluated at 12 concentrations in duplicate for IC50 determination.
- Biol, 2005, 12(7), 811-823) are kinases that also catalyze tau phosphorylation in the brain,
- CK15 mediates various processes in the brain including possible involvement in the glutamate deficiency associated with several neurodegenerative diseases (see, Perez DI, et al, Med. Res. Rev., 2011, 31(6), 924-954).
- Clk-1 although not part of the existing panel, will be added as in recent years many DYRK1A inhibitors have been shown to exhibit equipotent affinity for this kinase (see, Tahtouh, T., et al, J Med Chem 2012, 55, 9312-9330; Coombs, T.
- KinomeScanTM may be found at http://www.discoverx.com/services/drug-discovery- development-services/kinase-profiling/kinomescan).
- the 110 kinases comprised, the 96 diversity kinase set from DiscoveRx ⁇ , with an additional 14 kinases hand-picked for their involvement in CNS diseases. Note that members of the internal selectivity panel are included in the larger KinomeScanTM set.
- Standard MTT assays are used to measure cytotoxicity (loss of viable cells) of potential DYRKIA inhibitors.
- the MTT assay is a rapid, high-throughput assay for assessing cell metabolic activity.
- NAD(P)H- dependent cellular oxidoreductase enzymes reflect the number of viable cells present. These enzymes are capable of reducing the tetrazolium dye MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide to its insoluble formazan, which has a purple color. Cell viability is, therefore, directly proportional to the production of the purple formazan reaction product (CSF8a, Figure 1).
- the assay involves the use of recombinant DYRKIA protein and recombinant tau protein in a standard in vitro phosphorylation assay to assess the direct phosphorylation of tau by DYRKIA (see, Frost D, et al, PLoS One 2011;6:el9264).
- Cellular Activity Assay (CSF7, Box 10): Methodological details of the assay is previously described (see, Frost D, et al, PLoS One 2011 ;6:el9264).
- Harmine and EGCg improve cognitive performance in wild-type mice and Ts65Dn mice and their mode of action is postulated to be through DYRKIA inhibition (see, De la Torre R, et al, Mol Nutr Food Res 2014;58:278-288). Hence, it was proposed that inhibition of DYRKIA will improve cognitive performance in the Ts65Dn mice which experiments will directly evaluate using a battery of behavioral tests.
- DYRKIA kinase phosphorylates several cellular substrates in vivo (see, Smith B, et al, ACS Chem Neurosci 2012;3:857-872), including the microtubule associated protein tau (see, Ryoo SR, et al, J Biol Chem 2007;282:34850-34857) and the amyloid precursor protein (see, Ryoo SR, et al, J Neurochem 2008;104: 1333-1344).
- the combined effect of these phosphorylation events are to increase forms of hyperphosphorylated tau protein that are associated with neurodegeneration and to increase the production of neurotoxic amyloid beta peptides.
- This example provides information for specific benzimidazole compounds of the present invention: l-(4-methoxyphenyl)-6-(pyridin-4-yl)-lH-benzo[d]imidazole, 1.
- reaction was filtered through a celite pad, diluted with DCMTPA (3: 1, 10 mL), washed with NaHC0 3 (1 x 30 mL), H 2 0 (3 x 50 mL) and brine (1 x 100 mL), dried (MgSC ⁇ ) and concentrated under reduced pressure.
- the product was purified by silica gel column chromatography using an ISCO system (EtOAc/hexane, 0 to 80%).
- reaction was filtered through a celite pad, diluted with DCMTPA (3: 1 , 10 mL), washed with NaHC0 3 (1 x 30 mL), H 2 0 (3 x 50 mL) and brine (1 x 100 mL), dried (MgSC ⁇ ) and concentrated under reduced pressure.
- the product was purified by silica gel column chromatography using an ISCO system (EtOAc/hexane, 0 to 80%).
- reaction was filtered through a celite pad, diluted with DCMTPA (3: 1, 10 mL), washed with NaHC0 3 (1 x 30 mL), H 2 0 (3 x 50 mL) and brine (1 x 100 mL), dried (MgSC ⁇ ) and concentrated under reduced pressure.
- the product was purified by silica gel column chromatography using an ISCO system (EtOAc/hexane, 0 to 80%).
- Methyl 4-(6-bromo-lH-benzo[d]imidazol-l-yl) benzoate and reagents specified above were placed in a microwave vial, followed by addition of the designated solvent.
- the capped vial was purged with argon gas for 5 minutes.
- the reaction was then heated via microwave irradiation for 30 minutes at 130°C.
- the crude material was filtered through celite, and the celite flushed with methanol. The remaining solvent was evaporated in vacuo via azeotropic removal with toluene.
- 6-bromo-l-(3,4-dimethoxyphenyl)-lH-benzo[d]imidazole (0.300 mmol, 100 mg)
- pyridine-4- boronic acid 1.0 eq., 0.300 mmol, 38.8 mg
- Na2C03 4.0 eq., 1.20 mmol, 127 mg
- a mixture of 4: 1 DMF/water (3 mL) were added to a microwave vial.
- the vial was purged with Ar(g) then tris(dibenzylideneacetone)dipalladium (0) (Pd2(dba)3, 0.01 eq., 3.0 ⁇ , 2.9 mg) and tricyclohexylphosphine (0.03 eq., 9.0 ⁇ , 2.6 mg) was added.
- the reaction was microwave irradiated under Ar (g) at 130 °C for 30 min. then filtered through celite washing down with CH2CI2 and MeOH. The filtrate was evaporated in vacuo and DMF was removed by azeotroping with toluene.
- the crude material was purified via flash chromatography eluting with a
- 6-bromo-l-(3,4-ethylenedioxyphenyl)-lH-benzo[d]imidazole (0.151 mmol, 50.0 mg)
- pyridine- 4-boronic acid 1.0 eq., 0.151 mmol, 19.6 mg
- Na2C03 4.0 eq., 0.604 mmol, 64.0 mg
- a mixture of 4: 1 DMF/water (2 mL) were added to a microwave vial.
- the vial was purged with Ar(g) then tris(dibenzylideneacetone)dipalladium (0) (Pd2(dba)3, 0.01 eq., 1.6 ⁇ , 1.5 mg) and tricyclohexylphosphine (0.03 eq., 4.6 ⁇ , 1.4 mg) was added.
- the reaction was microwave irradiated under Ar (g) at 130 °C for 30 min. then filtered through celite washing down with CH2CI2 and MeOH. The filtrate was evaporated in vacuo and DMF was removed by azeotroping with toluene.
- 6-bromo-l-(3,4-methylenedioxyphenyl)-lH-benzo[d] imidazole 0.315 mmol, 100 mg
- 2-fluro- pyridine-4-boronic acid 1.0 eq., 0.315 mmol, 45.8 mg
- Na2C03 4.0 eq., 1.26 mmol, 134 mg
- a mixture of 4: 1 DMF/water 3.5 mL
- the vial was purged with Ar(g) then tris(dibenzylideneacetone)dipalladium (0) (Pd2(dba)3, 0.01 eq., 3.2 ⁇ , 3.0 mg) and tricyclohexylphosphine (0.03 eq., 9.5 ⁇ , 2.8 mg) was added.
- the reaction was microwave irradiated under Ar (g) at 130 °C for 30 min. then filtered through celite washing down with CH2CI2 and MeOH. The filtrate was evaporated in vacuo and DMF was removed by azeotroping with toluene.
- 6-bromo-l-(3,4-methylenedioxyphenyl)-lH-benzo[d] imidazole 0.315 mmol, 100 mg
- 2-fluro- pyridine-4-boronic acid 1.0 eq., 0.315 mmol, 43.2 mg
- Na2C03 4.0 eq., 1.26 mmol, 134 mg
- a mixture of 4: 1 DMF/water 3.5 mL
- the vial was purged with Ar(g) then tris(dibenzylideneacetone)dipalladium (0) (Pd2(dba)3, 0.01 eq., 3.2 ⁇ , 3.0 mg) and tricyclohexylphosphine (0.03 eq., 9.5 ⁇ , 2.8 mg) was added.
- the reaction was microwave irradiated under Ar (g) at 130 °C for 30 min. then filtered through celite washing down with CH2CI2 and MeOH. The filtrate was evaporated in vacuo and DMF was removed by azeotroping with toluene.
- the vial was purged with Ar(g) then tris(dibenzylideneacetone)dipalladium (0) (Pd2(dba)3, 0.01 eq., 3.2 ⁇ , 3.0 mg) and tricyclohexylphosphine (0.03 eq., 9.5 ⁇ , 2.8 mg) was added.
- the reaction was microwave irradiated under Ar (g) at 130 °C for 30 min. then filtered through celite washing down with CH2CI2 and MeOH. The filtrate was evaporated in vacuo and DMF was removed by azeotroping with toluene.
- 6-bromoimidazo[l,2-a]pyridine (7.61 mmol, 1.5 g), pyridine-4-boronic acid (1.0 eq., 7.61 mmol, 985 mg), Na 2 C0 3 (4.0 eq., 30.5mmol, 3.23 g), and a mixture of 4: 1 DMF/water (80 mL) were added to a microwave vial.
- the vial was purged with Ar(g) then
- the vial was purged with Ar(g) then tris(dibenzylideneacetone)dipalladium (0) (Pd 2 (dba)3, 0.01 eq., 2.4 ⁇ , 2.3 mg) and tricyclohexylphosphine (0.03 eq., 7.1 ⁇ , 2.1 mg) was added.
- the reaction was microwave irradiated under Ar (g) at 130 °C for 30 min. then filtered through celite washing down with
- 6-bromoimidazo[l,2-a]pyridine (4.06 mmol, 800 mg)
- lH-pyrazol-4-yl boronic acid pinacol ester (1.0 eq., 4.06 mmol, 829mg)
- Na 2 C0 3 (4.0 eq., 16.2 mmol, 1.72 g)
- a mixture of 4: 1 DMF/water (40 mL) were added to a microwave vial.
- the vial was purged with Ar(g) then tris(dibenzylideneacetone)dipalladium (0) (Pd2(dba)3, 0.01 eq., 0.041 mmol, 38.3 mg) and tricyclohexylphosphine (0.03 eq., 0.122 mmol, 35.2 mg) was added.
- the reaction was microwave irradiated under Ar (g) at 130°C for 30 min. then filtered through celite washing down with CH2CI2 and MeOH. The filtrate was evaporated in vacuo and DMF was removed by azeotroping with toluene.
- the vial was purged with Ar(g) then tris(dibenzylideneacetone)dipalladium (0) (Pd2(dba)3, 0.01 eq., 1.6 ⁇ , 1.5 mg) and tricyclohexylphosphine (0.03 eq., 4.7 ⁇ , 1.4 mg) was added.
- the reaction was microwave irradiated under Ar (g) at 130 °C for 30 min. then filtered through celite washing down with CH2CI2 and MeOH. The filtrate was evaporated in vacuo and DMF was removed by azeotroping with toluene.
- the vial was purged with Ar(g) then tris(dibenzylideneacetone)dipalladium (0) (Pd 2 (dba)3, 0.01 eq., 1.6 ⁇ , 1.5 mg) and tricyclohexylphosphine (0.03 eq., 4.7 ⁇ 1, 1.4 mg) was added.
- the reaction was microwave irradiated under Ar (g) at 130 °C for 30 min. then filtered through celite washing down with CH2CI2 and MeOH. The filtrate was evaporated in vacuo and DMF was removed by azeotroping with toluene.
- the vial was purged with Ar(g) then tris(dibenzylideneacetone)dipalladium (0) (Pd2(dba)3, 0.01 eq., 1.6 ⁇ , 1.5 mg) and tricyclohexylphosphine (0.03 eq., 4.7 ⁇ , 1.4 mg) was added.
- the reaction was microwave irradiated under Ar (g) at 130°C for 30 min. then filtered through celite washing down with CH2CI2 and MeOH. The filtrate was evaporated in vacuo and DMF was removed by azeotroping with toluene.
- the vial was purged with Ar(g) then tris(dibenzylideneacetone)dipalladium (0) (Pd2(dba)3, 0.01 eq., 1.6 ⁇ , 1.5 mg) and tricyclohexylphosphine (0.03 eq., 4.7 ⁇ , 1.4 mg) was added.
- the reaction was microwave irradiated under Ar (g) at 130 °C for 30 min. then filtered through celite washing down with CH2CI2 and MeOH. The filtrate was evaporated in vacuo and DMF was removed by azeotroping with toluene.
- the vial was purged with Ar(g) then tris(dibenzylideneacetone)dipalladium (0) (Pd2(dba)3, 0.01 eq., 1.6 ⁇ , 1.5 mg) and tricyclohexylphosphine (0.03 eq., 4.7 ⁇ , 1.4 mg) was added.
- the reaction was microwave irradiated under Ar (g) at 130 °C for 30 min. then filtered through celite washing down with CH2CI2 and MeOH. The filtrate was evaporated in vacuo and DMF was removed by azeotroping with toluene.
- the vial was purged with Ar(g) then tris(dibenzylideneacetone)dipalladium (0) (Pd2(dba)3, 0.01 eq., 1.6 ⁇ , 1.5 mg) and tricyclohexylphosphine (0.03 eq., 4.7 ⁇ , 1.4 mg) was added.
- the reaction was microwave irradiated under Ar (g) at 130 ° C for 30 min. then filtered through celite washing down with CH 2 CI 2 and MeOH. The filtrate was evaporated in vacuo and DMF was removed by azeotroping with toluene.
- the vial was purged with Ar(g) then tris(dibenzylideneacetone)dipalladium (0) (Pd2(dba)3, 0.01 eq., 1.6 ⁇ , 1.5 mg) and tricyclohexylphosphine (0.03 eq., 4.7 ⁇ , 1.4 mg) was added.
- the reaction was microwave irradiated under Ar (g) at 130 °C for 30 min. then filtered through celite washing down with CH2CI2 and MeOH. The filtrate was evaporated in vacuo and DMF was removed by azeotroping with toluene.
- the vial was purged with Ar(g) then tris(dibenzylideneacetone)dipalladium (0) (Pd2(dba)3, 0.01 eq., 1.6 ⁇ , 1.5 mg) and tricyclohexylphosphine (0.03 eq., 4.7 ⁇ , 1.4 mg) was added.
- the reaction was microwave irradiated under Ar (g) at 130 °C for 30 min. then filtered through celite washing down with CH2CI2 and MeOH. The filtrate was evaporated in vacuo and DMF was removed by azeotroping with toluene.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16843107.0A EP3344039A4 (en) | 2015-09-03 | 2016-09-02 | Small molecule inhibitors of dyrk1a and uses thereof |
US15/756,917 US10730842B2 (en) | 2015-09-03 | 2016-09-02 | Small molecule inhibitors of DYRK1A and uses thereof |
JP2018531299A JP2018526452A (en) | 2015-09-03 | 2016-09-02 | DYRK1A small molecule inhibitor and use thereof |
MX2018002631A MX2018002631A (en) | 2015-09-03 | 2016-09-02 | Small molecule inhibitors of dyrk1a and uses thereof. |
AU2016315881A AU2016315881B2 (en) | 2015-09-03 | 2016-09-02 | Small molecule inhibitors of DYRK1A and uses thereof |
CA2997556A CA2997556C (en) | 2015-09-03 | 2016-09-02 | Small molecule inhibitors of dyrk1a and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562213904P | 2015-09-03 | 2015-09-03 | |
US62/213,904 | 2015-09-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2017040993A1 true WO2017040993A1 (en) | 2017-03-09 |
WO2017040993A4 WO2017040993A4 (en) | 2017-05-26 |
Family
ID=58188489
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2016/050198 WO2017040993A1 (en) | 2015-09-03 | 2016-09-02 | Small molecule inhibitors of dyrk1a and uses thereof |
Country Status (7)
Country | Link |
---|---|
US (1) | US10730842B2 (en) |
EP (1) | EP3344039A4 (en) |
JP (1) | JP2018526452A (en) |
AU (1) | AU2016315881B2 (en) |
CA (1) | CA2997556C (en) |
MX (1) | MX2018002631A (en) |
WO (1) | WO2017040993A1 (en) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019031990A1 (en) * | 2017-08-07 | 2019-02-14 | Закрытое Акционерное Общество "Биокад" | Novel heterocyclic compounds as cdk8/19 inhibitors |
WO2019105886A1 (en) * | 2017-12-02 | 2019-06-06 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
WO2020069418A1 (en) * | 2018-09-28 | 2020-04-02 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of dyrk1/clk and uses thereof |
WO2020106685A1 (en) | 2018-11-19 | 2020-05-28 | Dana-Farber Cancer Institute, Inc. | Macrocyclic inhibitors of dyrk1a |
WO2020142486A1 (en) * | 2018-12-31 | 2020-07-09 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
RU2739489C2 (en) * | 2018-03-06 | 2020-12-24 | Закрытое Акционерное Общество "Биокад" | Novel heterocyclic compounds as cdk8/19 inhibitors |
JP2021503486A (en) * | 2017-11-20 | 2021-02-12 | アイカーン スクール オブ メディシン アット マウント サイナイ | Kinase Inhibitor Compounds and Compositions and Usage |
WO2021096314A1 (en) * | 2019-11-15 | 2021-05-20 | 가천대학교 산학협력단 | Novel benzimidazole derivative and use thereof |
WO2021126923A1 (en) * | 2019-12-19 | 2021-06-24 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Cd206 modulators their use and methods for preparation |
US11352328B2 (en) | 2016-07-12 | 2022-06-07 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus |
RU2782375C2 (en) * | 2017-12-02 | 2022-10-26 | Галапагос Нв | New compounds and their pharmaceutical compositions for treatment of diseases |
WO2023064366A1 (en) * | 2021-10-12 | 2023-04-20 | Biosplice Therapeutics, Inc. | Pyrrolo[2,1-f][1,2,4]triazines derivatives as inhibitors of dyrk1a |
WO2023107722A1 (en) * | 2021-12-10 | 2023-06-15 | Prothena Biosciences Limited | Compounds for use in treating neurological disorders |
WO2023107723A3 (en) * | 2021-12-10 | 2023-07-20 | Prothena Biosciences Limited | Cyclic compounds and their use for the treatment of neurological disorders |
US11788064B2 (en) | 2018-01-05 | 2023-10-17 | Icahn School Of Medicine At Mount Sinai | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition |
US11866427B2 (en) | 2018-03-20 | 2024-01-09 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114466840A (en) * | 2019-06-12 | 2022-05-10 | 威斯达研究所 | acetyl-CoA synthetase 2(ACSS2) inhibitors and methods of use thereof |
WO2022051291A2 (en) * | 2020-09-02 | 2022-03-10 | Ankh Life Sciences Limited | Inhibition of dyrk1a kinase |
CA3229864A1 (en) * | 2021-09-13 | 2023-03-16 | Provention Bio, Inc. | Methods and compositions comprising anti-cd3 antibodies and dyrk1a inhibitors for treating diabetes |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6218388B1 (en) * | 1997-08-20 | 2001-04-17 | Warner-Lambert Company | Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation |
US20050026960A1 (en) * | 2003-07-30 | 2005-02-03 | Agouron Pharmaceuticals, Inc. | 3, 5 disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
US7666879B2 (en) * | 2005-02-24 | 2010-02-23 | Eli Lilly And Company | Imidazo[1,2-A]pyridine compounds as VEGF-R2 inhibitors |
WO2013147711A1 (en) * | 2012-03-30 | 2013-10-03 | Agency For Science, Technology And Research | Bicyclic heterocyclic derivatives as mnk1 and mnk2 modulators and uses thereof |
WO2014096388A2 (en) * | 2012-12-21 | 2014-06-26 | Selvita S.A. | Novel benzimidazole derivatives as kinase inhibitors |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4331671A (en) | 1981-01-09 | 1982-05-25 | Sterling Drug Inc. | 5-(Pyridinyl)-1H-benzimidazoles and 1-hydroxy-6-(pyridinyl)-1H-benzimidazoles and their cardiotonic use |
EP1017682A4 (en) * | 1997-09-26 | 2000-11-08 | Merck & Co Inc | Novel angiogenesis inhibitors |
DE60109148T2 (en) * | 2000-04-28 | 2006-01-05 | Acadia Pharmaceuticals Inc., San Diego | muscarinic receptors |
PL366690A1 (en) * | 2004-03-29 | 2005-10-03 | Fundacja Rozwoju Diagnostyki I Terapii | New derivatives of 4,5,6,7-tetrabromobenzimidazole and method for their obtaining |
PE20081152A1 (en) | 2006-10-06 | 2008-08-10 | Wyeth Corp | N-SUBSTITUTED AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS |
JP2011528338A (en) * | 2008-07-18 | 2011-11-17 | サノフイ−アベンテイス | Novel imidazo [1,2-a] pyridine derivatives, process for their preparation, their use as pharmaceuticals, pharmaceutical compositions, and new uses, especially as MET inhibitors |
KR101685718B1 (en) | 2008-12-19 | 2016-12-12 | 제넨테크, 인크. | Heterocyclic compounds and methods of use |
JP5819831B2 (en) * | 2009-08-17 | 2015-11-24 | インテリカイン, エルエルシー | Heterocyclic compounds and their use |
US20110230481A2 (en) * | 2009-11-12 | 2011-09-22 | Selvita S.A. | Derivatives of tetrabromobenzimidazole, a process for the preparation thereof, a pharmaceutical composition comprising the same, a method of using the same, a method for modulating or regulating serine/threonine kinases, and serine/threonine kinases modulating agent |
WO2012174312A2 (en) * | 2011-06-15 | 2012-12-20 | Glaxosmithkline Llc | Benzimidazole derivatives as antiviral agents |
AU2012298510B2 (en) * | 2011-08-19 | 2016-10-27 | Diaxonhit | DYRK1 inhibitors and uses thereof |
JP5947465B2 (en) * | 2012-10-01 | 2016-07-06 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Benzimidazoles as CNS activators |
CA2906542A1 (en) | 2013-03-15 | 2014-09-25 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
GB2519623A (en) | 2013-06-18 | 2015-04-29 | 4Sc Discovery Gmbh | Method of inhibiting DYRK1B |
CN104447567B (en) | 2014-11-02 | 2016-06-29 | 湖南华腾制药有限公司 | A kind of preparation method of 1 substituted benzimidazole derivant |
-
2016
- 2016-09-02 JP JP2018531299A patent/JP2018526452A/en active Pending
- 2016-09-02 AU AU2016315881A patent/AU2016315881B2/en active Active
- 2016-09-02 EP EP16843107.0A patent/EP3344039A4/en not_active Withdrawn
- 2016-09-02 MX MX2018002631A patent/MX2018002631A/en unknown
- 2016-09-02 WO PCT/US2016/050198 patent/WO2017040993A1/en active Application Filing
- 2016-09-02 CA CA2997556A patent/CA2997556C/en active Active
- 2016-09-02 US US15/756,917 patent/US10730842B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6218388B1 (en) * | 1997-08-20 | 2001-04-17 | Warner-Lambert Company | Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation |
US20050026960A1 (en) * | 2003-07-30 | 2005-02-03 | Agouron Pharmaceuticals, Inc. | 3, 5 disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
US7666879B2 (en) * | 2005-02-24 | 2010-02-23 | Eli Lilly And Company | Imidazo[1,2-A]pyridine compounds as VEGF-R2 inhibitors |
WO2013147711A1 (en) * | 2012-03-30 | 2013-10-03 | Agency For Science, Technology And Research | Bicyclic heterocyclic derivatives as mnk1 and mnk2 modulators and uses thereof |
WO2014096388A2 (en) * | 2012-12-21 | 2014-06-26 | Selvita S.A. | Novel benzimidazole derivatives as kinase inhibitors |
Non-Patent Citations (3)
Title |
---|
BECKER ET AL.: "Activation, regulation, and inhibition of DYRK1A", FEBS JOURNAL., vol. 278, 3 December 2011 (2011-12-03), pages 246 - 256, XP055053004 * |
LONESCU ET AL.: "DYRK1A Kinase Inhibitors with Emphasis on Cancer", MINI REVIEWS IN MEDICINE CHEMISTRY., vol. 12, September 2012 (2012-09-01), pages 1 - 14, XP009180029 * |
See also references of EP3344039A4 * |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11352328B2 (en) | 2016-07-12 | 2022-06-07 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus |
CN111670183A (en) * | 2017-08-07 | 2020-09-15 | Biocad股份公司 | Novel heterocyclic compounds as CDK8/19 inhibitors |
AU2018312836B2 (en) * | 2017-08-07 | 2022-12-08 | Joint Stock Company "Biocad" | Novel heterocyclic compounds as CDK8/19 inhibitors |
JP7365332B2 (en) | 2017-08-07 | 2023-10-19 | ジョイント・ストック・カンパニー “バイオキャド” | Novel heterocyclic compounds as CDK8/19 inhibitors |
WO2019031990A1 (en) * | 2017-08-07 | 2019-02-14 | Закрытое Акционерное Общество "Биокад" | Novel heterocyclic compounds as cdk8/19 inhibitors |
JP2020530020A (en) * | 2017-08-07 | 2020-10-15 | ジョイント・ストック・カンパニー “バイオキャド” | A novel heterocyclic compound as a CDK8 / 19 inhibitor |
US11547712B2 (en) | 2017-11-20 | 2023-01-10 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
JP2021503486A (en) * | 2017-11-20 | 2021-02-12 | アイカーン スクール オブ メディシン アット マウント サイナイ | Kinase Inhibitor Compounds and Compositions and Usage |
CN111433200A (en) * | 2017-12-02 | 2020-07-17 | 加拉帕戈斯股份有限公司 | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
JP2021505553A (en) * | 2017-12-02 | 2021-02-18 | ガラパゴス・ナムローゼ・フェンノートシャップGalapagos N.V. | New compounds and their pharmaceutical compositions for the treatment of diseases |
JP7326276B2 (en) | 2017-12-02 | 2023-08-15 | ガラパゴス・ナムローゼ・フェンノートシャップ | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
CN111433200B (en) * | 2017-12-02 | 2024-03-22 | 加拉帕戈斯股份有限公司 | Compounds and pharmaceutical compositions for the treatment of diseases |
WO2019105886A1 (en) * | 2017-12-02 | 2019-06-06 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
RU2782375C2 (en) * | 2017-12-02 | 2022-10-26 | Галапагос Нв | New compounds and their pharmaceutical compositions for treatment of diseases |
AU2018374456B2 (en) * | 2017-12-02 | 2022-07-07 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
US11339166B2 (en) | 2017-12-02 | 2022-05-24 | Galapagos Nv | Compounds and pharmaceutical compositions thereof for the treatment of diseases |
US11788064B2 (en) | 2018-01-05 | 2023-10-17 | Icahn School Of Medicine At Mount Sinai | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition |
RU2739489C2 (en) * | 2018-03-06 | 2020-12-24 | Закрытое Акционерное Общество "Биокад" | Novel heterocyclic compounds as cdk8/19 inhibitors |
US11866427B2 (en) | 2018-03-20 | 2024-01-09 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
US20220041590A1 (en) * | 2018-09-28 | 2022-02-10 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of dyrk/clk and uses thereof |
CN113164476A (en) * | 2018-09-28 | 2021-07-23 | 代表亚利桑那大学的亚利桑那校董会 | Small molecule inhibitor of DYRK1/CLK and application thereof |
WO2020069418A1 (en) * | 2018-09-28 | 2020-04-02 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of dyrk1/clk and uses thereof |
EP3856186A4 (en) * | 2018-09-28 | 2022-07-06 | Arizona Board of Regents on behalf of the University of Arizona | Small molecule inhibitors of dyrk1/clk and uses thereof |
WO2020106685A1 (en) | 2018-11-19 | 2020-05-28 | Dana-Farber Cancer Institute, Inc. | Macrocyclic inhibitors of dyrk1a |
EP3906028A4 (en) * | 2018-12-31 | 2022-10-12 | Icahn School of Medicine at Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
CN113543783A (en) * | 2018-12-31 | 2021-10-22 | 西奈山伊坎医学院 | Kinase inhibitor compounds and compositions and methods of use |
WO2020142486A1 (en) * | 2018-12-31 | 2020-07-09 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
WO2021096314A1 (en) * | 2019-11-15 | 2021-05-20 | 가천대학교 산학협력단 | Novel benzimidazole derivative and use thereof |
CN115768757A (en) * | 2019-12-19 | 2023-03-07 | ***合众国,由健康及人类服务部部长代表 | CD206 modulators and uses and methods of making thereof |
WO2021126923A1 (en) * | 2019-12-19 | 2021-06-24 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Cd206 modulators their use and methods for preparation |
WO2023064366A1 (en) * | 2021-10-12 | 2023-04-20 | Biosplice Therapeutics, Inc. | Pyrrolo[2,1-f][1,2,4]triazines derivatives as inhibitors of dyrk1a |
WO2023107723A3 (en) * | 2021-12-10 | 2023-07-20 | Prothena Biosciences Limited | Cyclic compounds and their use for the treatment of neurological disorders |
WO2023107722A1 (en) * | 2021-12-10 | 2023-06-15 | Prothena Biosciences Limited | Compounds for use in treating neurological disorders |
Also Published As
Publication number | Publication date |
---|---|
CA2997556C (en) | 2020-12-22 |
AU2016315881A1 (en) | 2018-03-29 |
MX2018002631A (en) | 2019-02-07 |
JP2018526452A (en) | 2018-09-13 |
EP3344039A4 (en) | 2019-08-28 |
CA2997556A1 (en) | 2017-03-09 |
US10730842B2 (en) | 2020-08-04 |
US20190062284A1 (en) | 2019-02-28 |
EP3344039A1 (en) | 2018-07-11 |
AU2016315881B2 (en) | 2019-09-19 |
WO2017040993A4 (en) | 2017-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2016315881B2 (en) | Small molecule inhibitors of DYRK1A and uses thereof | |
JP6982343B2 (en) | Therapeutic inhibitor compound | |
JP6768857B2 (en) | Lysine-specific inhibitor of demethylase-1 | |
KR102400920B1 (en) | Inhibitors of lysine specific demethylase-1 | |
RU2637936C2 (en) | Inhibitors of lrrk2 kinases activity | |
KR102534962B1 (en) | 8,9-dihydroimidazole[1,2-a]pyrimido[5,4-e]pyrimidine-5(6H)-ketone compound | |
EP3318561B1 (en) | Heteroaryl compounds and methods of use thereof | |
TWI527800B (en) | 1-(arylmethyl)quinazoline-2,4(1h,3h)-diones as parp inhibitors and the use thereof | |
EP2909193B1 (en) | Phenyl linked quinolinyl modulators of ror-gamma-t | |
CA2982588A1 (en) | Bromodomain inhibitors | |
EP3394052B1 (en) | Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity | |
US10287293B2 (en) | Bicyclic heterocyclic compounds as PDE2 inhibitors | |
CN103570625A (en) | N-(3-aryl-heteroaryl)-4-aryl-aryl carboxamide and analog as hedgehog pathway inhibitors and application thereof | |
Garofalo et al. | Selective inhibitors of G2019S-LRRK2 kinase activity | |
DK2817302T3 (en) | 1H-indazole-3-carboxamide compounds as glycogen synthase kinase-3 beta inhibitors | |
JP2018516278A (en) | Use of pteridinone derivatives as EGFR inhibitors | |
AU2015276699A1 (en) | Pyridino[1,2-a]pyrimidone analogue used as PI3K inhibitor | |
EP3476846A1 (en) | Novel heterocyclic derivative compound and use thereof | |
Gao et al. | Discovery and anti-inflammatory evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β) | |
Liu et al. | Discovery of novel β-carboline-1, 2, 3-triazole hybrids as AChE/GSK-3β dual inhibitors for Alzheimer's disease treatment | |
KR20150021120A (en) | Heteroaryl compounds and methods of use thereof | |
CN114133394B (en) | Compound selectively aiming at activity of cell cycle dependent kinase 12, preparation method and medical application | |
US20170305913A1 (en) | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group ii metabotropic glutamate receptors | |
WO2008022747A1 (en) | Tricyclic lactam derivatives, their manufacture and use as pharmaceutical agents | |
EP2825166A1 (en) | Method of treating ophthalmic conditions with kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16843107 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2018/002631 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2997556 Country of ref document: CA Ref document number: 2018531299 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2016315881 Country of ref document: AU Date of ref document: 20160902 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2016843107 Country of ref document: EP |